<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753270</url>
  </required_header>
  <id_info>
    <org_study_id>12683</org_study_id>
    <nct_id>NCT02753270</nct_id>
  </id_info>
  <brief_title>Catheter-directed Foam Sclerotherapy With Tumescence</brief_title>
  <official_title>Catheter-directed Foam Sclerotherapy With Tumescence of the Great Saphenous Vein Versus Ultrasound Guided Foam Sclerotherapy: Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Foam sclerotherapy has been established as another option of treatment for varicose veins of
      the lower limbs. Its advantages are the application to patients with high surgical risk and
      immediate return to usual activities. Comparing to laser and radiofrequency, it has lower
      cost and is less painful. Nevertheless, it requires more re-interventions due to venous
      recanalization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare two ultrasound guided foam sclerotherapy (UGFS)
      techniques to great saphenous vein (GSV) by injecting the sclerosant foam through a short
      catheter without perivenous tumescence and through a long catheter with saline anesthetic
      tumescence. Method: selection of 50 patients with primary varicose veins, edema (C3EpAsPr of
      the CEAP classification) and with GSV measuring 6 - 10 mm, 3 cm below the saphenofemoral
      junction, identified by ultrasound. The study is taking place at the vascular surgery
      ambulatory of the University of São Paulo. It is a prospective controlled trial with random
      allocation in two groups according to the foam sclerosant technique injection. The group 1
      will receive the sclerosant foam by a short catheter 18 G and in the group 2 an angiographic
      catheter 4 Fr. will be used. All patients will be treated with 3% polidocanol foam prepared
      with a three-way tap and two plastic disposable syringes, according to Tessari's method. The
      access will be by puncture and its place will depend on the insufficient venous extension. It
      will be at the level of the knee to treat proximal GSV or at the medial ankle to treat the
      full length of the vein. In group 2, after inserting the long catheter into the GSV, a saline
      anesthetic solution will be infiltrated around the insufficient venous segment under
      ultrasound guidance to reduce its diameter. The long catheter will be continuously flushed
      with 0.9% saline solution until the foam sclerosant injection. In the cases of treating only
      the proximal GSV, patients will receive a continuous compression with tourniquet below the
      knee just before the injection and maintained for 5 minutes thereafter. Then, the tributaries
      in all 50 patients will be treated by phlebectomy under tumescent local anesthesia.
      Color-duplex ultrasound follow-up is programmed to 7, 28 and 168 days after the treatment.
      The first one is to check the possibility of deep venous thrombosis, the second is to verify
      the occlusion rate and the need of another foam injection. The last ultrasound is to check
      the final occlusion rate.

      Hypothesis: UGFS with long catheter preceded of tumescence has a large occlusion rate of the
      GSV with monotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Great Saphenous Vein Occlusion Rate</measure>
    <time_frame>Six months after the intervention</time_frame>
    <description>It will be measured by ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Change</measure>
    <time_frame>Six months follow-up after the intervention</time_frame>
    <description>It will be measured by the application of the Aberdeen varicose vein questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>From the intervention until six months follow-up</time_frame>
    <description>It will be considered:
anaphylaxis;
superficial thrombophlebitis;
deep venous thrombosis;
pulmonary embolism;
visual disturbances;
migraine;
transient ischemic attack;
tissue necrosis;
intra arterial injection;
neurological injury;
edema;
skin pigmentation;
skin irritation;
burning after the sclerosant injection;
retaining clots.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Varicose Vein of Lower Limbs</condition>
  <arm_group>
    <arm_group_label>Short catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twenty-five patients will receive the sclerosant foam by a short catheter 18 G. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long catheter preceded by tumescence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twenty-five patients will be receive foam sclerosant by an angiographic catheter 4 French. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Short catheter</intervention_name>
    <description>Ultrasound Guided Foam Sclerotherapy in Great Saphenous Vein, measuring from 6 to 10 mm, with Short Catheter.</description>
    <arm_group_label>Short catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Long catheter preceded by tumescence</intervention_name>
    <description>Ultrasound Guided Foam Sclerotherapy Transcatheter in Great Saphenous Vein, measuring from 6 to 10 mm, Preceded by Tumescence.</description>
    <arm_group_label>Long catheter preceded by tumescence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal to or greater than 18 years;

          -  patients with varicose veins with edema - CEAP classification C3EpAsPr;

          -  Great saphenous vein incompetence, segmental and total, with diameter from 6 to 10 mm
             in proximal thigh, 3 cm from the saphenous femoral junction measured by ultrasound.

        Exclusion Criteria:

          -  Allergy to the sclerosant substance;

          -  acute deep vein thrombosis or pulmonary thromboembolism;

          -  local infection in the area of sclerotherapy or severe systemic infection;

          -  prolonged immobilisation;

          -  symptomatic patent foramen ovale;

          -  pregnancy;

          -  peripheral arterial occlusive disease;

          -  short saphenous vein incompetence association;

          -  refusal to sign the consent form;

          -  nonadherence to outpatient treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erasmo S Silva, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>São Paulo University</affiliation>
  </overall_official>
  <results_reference>
    <citation>Breu FX, Guggenbichler S, Wollmann JC. 2nd European Consensus Meeting on Foam Sclerotherapy 2006, Tegernsee, Germany. Vasa. 2008 Feb;37 Suppl 71:1-29.</citation>
    <PMID>18426039</PMID>
  </results_reference>
  <results_reference>
    <citation>Cavezzi A, Tessari L. Foam sclerotherapy techniques: different gases and methods of preparation, catheter versus direct injection. Phlebology. 2009 Dec;24(6):247-51. doi: 10.1258/phleb.2009.009061. Review.</citation>
    <PMID>19952380</PMID>
  </results_reference>
  <results_reference>
    <citation>Gohel MS, Epstein DM, Davies AH. Cost-effectiveness of traditional and endovenous treatments for varicose veins. Br J Surg. 2010 Dec;97(12):1815-23. doi: 10.1002/bjs.7256. Epub 2010 Oct 4.</citation>
    <PMID>20922783</PMID>
  </results_reference>
  <results_reference>
    <citation>Parsi K, Exner T, Connor DE, Ma DD, Joseph JE. In vitro effects of detergent sclerosants on coagulation, platelets and microparticles. Eur J Vasc Endovasc Surg. 2007 Dec;34(6):731-40. Epub 2007 Oct 4.</citation>
    <PMID>17919946</PMID>
  </results_reference>
  <results_reference>
    <citation>Rasmussen LH, Lawaetz M, Bjoern L, Vennits B, Blemings A, Eklof B. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg. 2011 Aug;98(8):1079-87. doi: 10.1002/bjs.7555.</citation>
    <PMID>21725957</PMID>
  </results_reference>
  <results_reference>
    <citation>Coleridge-Smith P, Labropoulos N, Partsch H, Myers K, Nicolaides A, Cavezzi A. Duplex ultrasound investigation of the veins in chronic venous disease of the lower limbs--UIP consensus document. Part I. Basic principles. Eur J Vasc Endovasc Surg. 2006 Jan;31(1):83-92. Epub 2005 Oct 14. Review.</citation>
    <PMID>16226898</PMID>
  </results_reference>
  <results_reference>
    <citation>Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg. 2001 Jan;27(1):58-60.</citation>
    <PMID>11231246</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Jorgete Barreto dos Santos</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/18426039</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/19952380</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Literature Review</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/20922783</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Literature Review</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=In+vitro+effects+of+detergent+sclerosants+on+coagulation%2C+platelets+and+microparticles.</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Literature Review</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/21725957</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Literature Review</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/16226898</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Literature Review</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/11231246</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

